Category: VLP technology

FDA approves IND application for peanut allergen vaccine. Phase I study in peanut allergy patients to begin May 2022

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022 Topline data from first-in-human trial expected in H1 2023 Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of …

Read More

Peanut allergy vaccine takes big step forward with first human tests

From The Telegraph, By Julia Bradshaw If clinical trials are successful, the British-developed jab could be available to patients within four to five years The world is one step closer to a vaccine against peanut allergy after UK biotech Allergy Therapeutics announced plans to test its jab in human clinical trials. The company, which was …

Read More

Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH

Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …

Read More